ABL Bio Inc. (KOSDAQ: 298380)
South Korea flag South Korea · Delayed Price · Currency is KRW
40,500
+5,400 (15.38%)
Oct 11, 2024, 9:00 AM KST

ABL Bio Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21
Operating Revenue
32,95565,54767,3015,332
Other Revenue
00-00
Revenue
32,95565,54767,3015,332
Revenue Growth (YoY)
-66.11%-2.61%1162.19%-
Cost of Revenue
62.7446.2583.7647.98
Gross Profit
32,89265,50167,2175,284
Selling, General & Admin
15,52613,49315,56913,962
Research & Development
55,78952,03548,41641,034
Operating Expenses
73,83868,11866,30956,472
Operating Income
-40,946-2,617908-51,188
Interest Expense
-850.95-2,151-1,326-41.98
Interest & Investment Income
1,1231,294233.7599.72
Currency Exchange Gain (Loss)
448.69734.041,761864.43
Other Non Operating Income (Expenses)
-679.52-1,0372,17647.62
EBT Excluding Unusual Items
-40,905-3,7763,753-50,218
Gain (Loss) on Sale of Investments
904.991,132-592.136,666
Gain (Loss) on Sale of Assets
-2.64-2.6448-5.83
Pretax Income
-40,003-2,6473,209-43,558
Net Income
-40,003-2,6473,209-43,558
Net Income to Common
-40,003-2,6473,209-43,558
Shares Outstanding (Basic)
48484847
Shares Outstanding (Diluted)
48484847
Shares Change (YoY)
0.29%0.58%1.27%-
EPS (Basic)
-835.12-55.3267.46-927.36
EPS (Diluted)
-835.12-55.3267.46-927.36
Free Cash Flow
-73,486-34,10270,076-41,850
Free Cash Flow Per Share
-1534.13-712.771473.24-890.99
Gross Margin
99.81%99.93%99.88%99.10%
Operating Margin
-124.25%-3.99%1.35%-959.99%
Profit Margin
-121.39%-4.04%4.77%-816.91%
Free Cash Flow Margin
-222.99%-52.03%104.12%-784.87%
EBITDA
-38,424-27.323,233-49,029
EBITDA Margin
-116.60%-0.04%4.80%-
D&A For EBITDA
2,5222,5902,3252,158
EBIT
-40,946-2,617908-51,188
EBIT Margin
-124.25%-3.99%1.35%-
Source: S&P Capital IQ. Standard template. Financial Sources.